Again I disagree. You have constructed a house of cards built on an indefensible and implausible foundation.

IPIX management has made it clear that they are seeking partnerships.

There is absolutely no justification for starting with a premise that there is only one big pharma that would be interested in whichever drug or application to be be partnered, particularly since we have been told that there are multiple non-disclosure agreements signed with more than one other company.

Your claim that whatever deal is eventually reached would pay less than shareholders hope, because there would be only one bidder, is false both for that reason, and because the company still has adequate funding to continue with clinical trials without a partner. (Admittedly, the Brilacidin-ABSSSI study would need to continue on hold until such a partnership is achieved.)

And again, you are sowing fear, uncertainty, and doubt by claiming that Mr. Ehrlich, Dr. Menon, and the staff will strike deals that benefit themselves at the expense of shareholders.

I like to give new posters the benefit of the doubt, but in this case, you've had two strikes, and I don't need a third strike to call you out.